XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Financial Instruments (Narrative) (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Sep. 02, 2020
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Realized investment gains (losses) $ 0 $ 0 $ 0 $ 0    
Change in fair value of contingent consideration     (12,170,000) 21,900,000    
Business combination, contingent consideration, liability 51,700,000   51,700,000   $ 63,900,000  
Ascyrus Medical LLC            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Percentage of outstanding equity acquired           100.00%
Maximum amount of future consideration payment           $ 100,000,000.0
Change in fair value of contingent consideration $ 3,500,000 $ 6,200,000 $ (12,200,000) $ 21,900,000    
Ascyrus Medical LLC | Measurement Input, Discount Rate            
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]            
Contingent consideration, measurement input 0.16   0.16